User profiles for "author:G J Peters"
 | GJ PetersProfessor of Pharmacology of Cytostatics, Amsterdam UMC, location VUMC, Amsterdam; … Verified email at amsterdamumc.nl Cited by 55564 |
[HTML][HTML] Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism
GJ Peters, HHJ Backus, S Freemantle… - … et Biophysica Acta (BBA …, 2002 - Elsevier
Thymidylate synthase (TS) is a key enzyme in the de novo synthesis of 2′-deoxythymidine-
5′-monophosphate (dTMP) from 2′-deoxyuridine-5′-monophosphate (dUMP), for which …
5′-monophosphate (dTMP) from 2′-deoxyuridine-5′-monophosphate (dUMP), for which …
Basis for effective combination cancer chemotherapy with antimetabolites
GJ Peters, CL Van der Wilt, CJA Van Moorsel… - Pharmacology & …, 2000 - Elsevier
Most current chemotherapy regimens for cancer consist of empirically designed
combinations, based on efficacy and lack of overlapping toxicity. In the development of …
combinations, based on efficacy and lack of overlapping toxicity. In the development of …
Determinants of resistance to 2′, 2′-difluorodeoxycytidine (gemcitabine)
AM Bergman, HM Pinedo, GJ Peters - Drug Resistance Updates, 2002 - Elsevier
The inherent or induced resistance of tumors to cytostatic agents is a major clinical problem.
In this review, we summarize the pre-clinical mechanisms of acquired and inherent …
In this review, we summarize the pre-clinical mechanisms of acquired and inherent …
MRP3, an organic anion transporter able to transport anti-cancer drugs
M Kool, M Van Der Linden, M de Haas… - Proceedings of the …, 1999 - National Acad Sciences
The human multidrug-resistance protein (MRP) gene family contains at least six members:
MRP1, encoding the multidrug-resistance protein; MRP2 or cMOAT, encoding the …
MRP1, encoding the multidrug-resistance protein; MRP2 or cMOAT, encoding the …
Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2
JH Hooijberg, HJ Broxterman, M Kool, YG Assaraf… - Cancer research, 1999 - AACR
Transfection of multidrug resistance proteins (MRPs) MRP1 and MRP2 in human ovarian
carcinoma 2008 cells conferred a marked level of resistance to short-term (1–4 h) exposure …
carcinoma 2008 cells conferred a marked level of resistance to short-term (1–4 h) exposure …
Molecular basis of bortezomib resistance: proteasome subunit β5 (PSMB5) gene mutation and overexpression of PSMB5 protein
R Oerlemans, NE Franke, YG Assaraf… - Blood, The Journal …, 2008 - ashpublications.org
The proteasome inhibitor bortezomib is a novel anticancer drug that has shown promise in
the treatment of refractory multiple myeloma. However, its clinical efficacy has been …
the treatment of refractory multiple myeloma. However, its clinical efficacy has been …
Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing
YP Keepers, PE Pizao, GJ Peters, J van Ark-Otte… - European Journal of …, 1991 - Elsevier
The sulforhodamine B (SRB) protein stain assay was compared with the tetrazolium (MTT)
colorimetric assay for in vitro chemosensitivity testing of various human tumour cell lines …
colorimetric assay for in vitro chemosensitivity testing of various human tumour cell lines …
MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity
E Giovannetti, N Funel, GJ Peters, M Del Chiaro… - Cancer research, 2010 - AACR
Abstract MicroRNA-21 (miR-21) was reported to be overexpressed and contributes to
invasion and gemcitabine resistance in pancreatic ductal adenocarcinoma (PDAC). The aim …
invasion and gemcitabine resistance in pancreatic ductal adenocarcinoma (PDAC). The aim …
[HTML][HTML] Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer
JH Hwang, J Voortman, E Giovannetti, SM Steinberg… - PloS one, 2010 - journals.plos.org
Background Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis. The high
risk of recurrence following surgical resection provides the rationale for adjuvant therapy …
risk of recurrence following surgical resection provides the rationale for adjuvant therapy …
Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance
KJ Gotink, HJ Broxterman, M Labots, RR De Haas… - Clinical Cancer …, 2011 - AACR
Purpose: Resistance to antiangiogenic tyrosine kinase inhibitors such as sunitinib is an
important clinical problem, but its underlying mechanisms are largely unknown. We …
important clinical problem, but its underlying mechanisms are largely unknown. We …